Navigation Links
Antibody key to treating variant CJD, scientists find
Date:3/4/2009

Scientists at the University of Liverpool have determined the atomic structure of the 'binding' between a brain protein and an antibody that could be key to treating patients with diseases such as variant CJD.

Variant Creutzfeldt-Jakob Disease (vCJD) is part of a family of rare progressive neurodegenerative disorders, called prion diseases, which affect both animals and humans. It is thought that those who have developed vCJD became infected through the consumption of cattle products contaminated with Bovine Spongiform Encephalopathy (BSE) a brain disorder in cows, commonly known as Mad Cow Disease.

Prion diseases can develop when a naturally occurring brain prion protein called, PrP, comes into contact with infectious prions. This converts PrP into a form that has a different shape, and eventually leads to a build-up of protein in the brain, causing brain cells to die. It is thought that immunisation with antibodies that can 'stick' to PrP could treat and even prevent the development of the disease.

To understand the 'connection' between the antibody and the protein, scientists at Liverpool used X-ray crystallography technology to build a three-dimensional picture of the binding between an antibody called ICSM18 designed to 'stick' effectively to prion proteins and PrP cells.

Samar Hasnain, Professor of Molecular Biophysics at the University, explains: "To pin-point where the antibody 'sticks' to the protein we used X-ray crystallography, pioneered by Nobel Prize winner Max Perutz. Significantly we found that the point at which the protein and antibody came together was also where scientists at the Medical Research Council (MRC) Prion Unit had identified a single amino acid, which we now know has a significant impact on a patient's susceptibility to prion disease."

Scientists at the MRC Prion Unit, University College London, who collaborated on the research, have found that ICSM18 could help prevent brain cells from becoming infected as well as reverse early damage caused by the disease.

Professor John Collinge, Director of the MRC Prion Unit, added: "We have shown that ICSM18 has the highest therapeutic potential in animal and cell based studies, but we have yet to establish its impact on people who have vCJD or other prion diseases. We are currently working, however, to make human versions of the antibodies for future trials in people."


'/>"/>

Contact: Samantha Martin
samantha.martin@liv.ac.uk
44-151-794-2248
University of Liverpool
Source:Eurekalert

Related biology news :

1. UC San Diego and Genentech scientists develop potentially disruptive antibody sequencing technology
2. ETH Zurich researchers develop antibody test
3. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
4. Yale chemist receives NIH Young Investigator Award for antibody targeting
5. Reversing cognitive deficits: Injectable antibody may attack source of problem
6. Studies point to novel target for treating arrhythmias
7. World breakthrough in treating premature babies
8. UC Davis discovery offers hope for treating kidney cancer
9. Pitt research identifies new target in brain for treating schizophrenia
10. Commercial aquatic plants offer cost-effective method for treating wastewater
11. New approach to treating cystic fibrosis lung infection shows promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/1/2016)... -- Rising sales of consumer electronics coupled ... gesture control market size through ... electronics coupled with new technological advancements to drive global ... through 2020   --> Rising ... to drive global touchfree intuitive gesture control market ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: ... pleased to announce that Mitsui & Co. Ltd., its ... succinic acid plant, is investing an additional CDN$25 million ... increasing its stake from 30% to 40%.  Mitsui will ... bio-succinic acid produced in Sarnia , ...
(Date:2/10/2016)... is introducing a hybrid membership model which will provide ... joining or renewing through an organizational purchasing model. For ... employee in any size association or AMC office can ... benefits.   John H. Graham, IV , ... organizations of any size and their employees to gain ...
(Date:2/10/2016)... , Feb. 10, 2016  Matchbook, Inc., ... for fast growing biotech companies, announced today the ... Procurement Strategic Advisor. Jim brings nearly 25 years ... and procurement, having spent nearly two decades in ... Chain/Logistics and Procurement at Genzyme and, most recently ...
(Date:2/10/2016)... ... 2016 , ... SonaCare Medical, LLC reports the introduction of ... monitoring. The inaugural launch of this new technology occurred over the course of ... to a HIFU technical expert at SonaCare Medical headquarters. , Sonalink allows ...
Breaking Biology Technology: